PT85572A - Polypeptide des rhinovirusstammes hrv89 sowie die hierfuer codierenden dna-molekuele - Google Patents

Polypeptide des rhinovirusstammes hrv89 sowie die hierfuer codierenden dna-molekuele

Info

Publication number
PT85572A
PT85572A PT85572A PT8557287A PT85572A PT 85572 A PT85572 A PT 85572A PT 85572 A PT85572 A PT 85572A PT 8557287 A PT8557287 A PT 8557287A PT 85572 A PT85572 A PT 85572A
Authority
PT
Portugal
Prior art keywords
herefuer
hrv89
polypeptides
dna molecules
coding dna
Prior art date
Application number
PT85572A
Other languages
German (de)
English (en)
Other versions
PT85572B (pt
Inventor
Markus Duechler
Tim Skern
Wolfgang Sommergruber
Christoph Neubauer
Peter Grundler
Dieter Blaas
Ernst Kuechler
Ljerka Frasel
Manfred Zorn
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19863628658 external-priority patent/DE3628658A1/de
Priority claimed from DE19873701301 external-priority patent/DE3701301A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PT85572A publication Critical patent/PT85572A/pt
Publication of PT85572B publication Critical patent/PT85572B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/106—Picornaviridae (F), e.g. hepatitis A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32711—Rhinovirus
    • C12N2770/32734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT85572A 1986-08-23 1987-08-21 Processo para a preparacao de polipeptidos da estirpe de rhinovirus hrv89 assim como de moleculas de dna que os codificam e de composicoes farmaceuticas que os contem PT85572B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863628658 DE3628658A1 (de) 1986-08-23 1986-08-23 Polypeptide des rhinovirusstammes hrv89 sowie die hierfuer codierenden dna-molekuele
DE19873701301 DE3701301A1 (de) 1987-01-17 1987-01-17 Herstellung von expressionsplasmiden fuer die viralen huellenproteinbereiche von hrv2 und hrv89

Publications (2)

Publication Number Publication Date
PT85572A true PT85572A (de) 1987-09-01
PT85572B PT85572B (pt) 1990-05-31

Family

ID=25846814

Family Applications (1)

Application Number Title Priority Date Filing Date
PT85572A PT85572B (pt) 1986-08-23 1987-08-21 Processo para a preparacao de polipeptidos da estirpe de rhinovirus hrv89 assim como de moleculas de dna que os codificam e de composicoes farmaceuticas que os contem

Country Status (9)

Country Link
EP (1) EP0261403A3 (pt)
KR (1) KR880003006A (pt)
AU (1) AU617982B2 (pt)
DK (1) DK438187A (pt)
FI (1) FI873615L (pt)
IL (1) IL83607A (pt)
NO (1) NO873535L (pt)
NZ (1) NZ221537A (pt)
PT (1) PT85572B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2068855T3 (es) * 1988-07-25 1995-05-01 Boehringer Ingelheim Int Sintesis in vitro de un arn infeccioso.
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
ZA896668B (en) * 1988-09-01 1990-06-27 Molecular Therapeutics Inc A human rhinovirus receptor protein that inhibits virus infectivity
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
DE68929096T2 (de) 1988-09-01 2000-05-11 Bayer Corp., Pittsburgh Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US5686582A (en) * 1990-07-20 1997-11-11 Bayer Corporation Multimeric forms of human rhinovirus receptor protein
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
EP0468257B1 (en) * 1990-07-20 1999-09-01 Bayer Corporation Multimeric form of human rhinovirus receptor protein
US5674982A (en) * 1990-07-20 1997-10-07 Bayer Corporation Multimeric form of human rhinovirus receptor protein
EP2316481A1 (en) * 2009-10-30 2011-05-04 Biomay Ag Pharmaceutical composition for the treatment and prevention of a rhinovirus infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0169146A3 (en) * 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
DE3505148A1 (de) * 1985-02-15 1986-10-30 Boehringer Ingelheim International GmbH, 6507 Ingelheim Polypeptide des rhinovirusstammes hrv2 sowie die hierfuer codierenden dna-molekuele

Also Published As

Publication number Publication date
FI873615A7 (fi) 1987-12-18
FI873615L (fi) 1988-02-24
PT85572B (pt) 1990-05-31
IL83607A0 (en) 1988-01-31
FI873615A0 (fi) 1987-08-21
DK438187A (da) 1988-02-24
NZ221537A (en) 1991-07-26
EP0261403A2 (de) 1988-03-30
AU617982B2 (en) 1991-12-12
NO873535D0 (no) 1987-08-21
EP0261403A3 (de) 1988-04-13
KR880003006A (ko) 1988-05-13
DK438187D0 (da) 1987-08-21
AU7733387A (en) 1988-03-24
IL83607A (en) 1992-05-25
NO873535L (no) 1988-02-24

Similar Documents

Publication Publication Date Title
DK100985A (da) Dna, der koder for human tumornecrosefaktor, samt humant tumornecrosefaktor-polypeptid og fremgangsmaader til fremstilling heraf
DE3165463D1 (en) Dna sequences, recombinant dna molecules and processes for producing human interferon-alpha like polypeptides
DK3687D0 (da) Polypeptider og fremgangsmaade til fremstilling deraf
DK166087D0 (da) Proteiner og fremgangsmaade til fremstilling deraf
NO168116C (no) Hydrolyserbart harpikspreparat og dets anvendelse
IT1203375B (it) Catalizzatori complessi di stagno o bismuto e indurimento attinato di investimenti con essi
DK54686D0 (da) Sammensatte keramiske genstande og fremgangsmaade til fremstilling deraf
DK122687A (da) Polypeptid, dna og anvendelse deraf
DE3752319D1 (de) Prozess zur rekombinanten Herstellung von HIV-2 - Proteinen sowie Zellen, die HIV-2 - Proteine exprimiert
ZA86217B (en) Dna sequences,recombinant dna molecules and processes for producing human lipocortin-like polypeptides
IT8823098A0 (it) Procedimento per la sintesi di peptidi retro-inversi e nuovi intermedi in tale procedimento
PT82026A (de) Polupeptide des rhinovirusstammes hrv2 sowie die hierfuer codierenden dna-molekuele
DK467487A (da) Polypeptid, anvendeligt til lindring, behandling og diagnosticering af autoimmunitetssygdomme, isaer arthritis
DE3774761D1 (de) Dpcm-kodierer und zugehoeriger dekodierer.
PT85572A (de) Polypeptide des rhinovirusstammes hrv89 sowie die hierfuer codierenden dna-molekuele
ZA876248B (en) Polypeptides of the rhinovirus strain hrv89 and the dna molecules coding therefor
NO872323L (no) Harpiksprodukt og fremgangsmaate for dets fremstilling.
DK64387D0 (da) Beskyttende overtraeksmateriale og dets anvendelse
DE3585890D1 (de) Peptid und dafuer kodierendes gen.
DK502988D0 (da) Polypeptider med interferon- eller interferon-gamma-lignende aktivitet, fremgangsmaade til fremstilling deraf, vektorer, der koder disse polypeptider og farmaceutiske praeparater indeholdende saadanne
KR880700634A (ko) 세포막 조절제의 용도 및 그 세포막 조절제로 구성된 제품
DK203087D0 (da) Proteiner og fremgangsmaade til fremstilling deraf
IE860414L (en) "polypeptides of the rhinovirus strain hrv2 and the dna¹molecules coding therefor"
IE872242L (en) Polypeptodes of the rhinovirus strain HRV89 and the DNA¹molecules coding therefor
DK266187A (da) Rekombinant humant protein s, fremgangsmaade til fremstilling heraf og rekombinant dna-vektor til brug ved fremgangsmaaden

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19940531